EVGN News

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

EVGN

REHOVOT, Israel, Aug. 28, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology and chemistry company, today announced that Ofer Haviv, Evogene's President and CEO, will present at the H.C. Wainwright 27th Annual Global Investment Conference, 2025,...

Evogene Reports Second Quarter 2025 Financial Results

EVGN

Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene's consolidated statements of...

August 19, 2025Earnings
Read more →

Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

EVGN

A failure in metabolite breakdown leads to their ordered self-assembly into pathological aggregates, such as in Tyrosinemia and Gout. REHOVOT, Israel, Aug. 12, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq, TASE: EVGN), a leading computational biology and chemistry company, today announced a...

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

EVGN

June 10, 2025
Read more →

Lake Street Maintains Buy on Evogene, Lowers Price Target to $3.5

EVGN

May 22, 2025
Read more →

Evogene Q1 EPS $(0.38) Beats $(0.63) Estimate, Sales $2.44M Miss $4.42M Estimate

EVGN

May 21, 2025
Read more →

ICL To Acquire Majority Activity Of Evogene's Subsidiary Lavie Bio; Term Not Disclosed

EVGN

April 21, 2025
Read more →

During Q4 2024 And The Beginning Of 2025, Evogene Established An Expense Reduction Plan, To Better Align With Its Strategic Goals, Leading To A Reduction Of ~30% In Headcount, To Be Completed By The End Of Q1 2025

EVGN

March 6, 2025
Read more →

Evogene Q4 2024 GAAP EPS $0.06 May Not Be Comparable To $(0.72) Estimate, Sales $1.61M Miss $3.63M Estimate

EVGN

March 6, 2025
Read more →

AgPlenus Announces Discovery Of New Mode Of Action For Fungicides Against Wheat Disease

EVGN

February 13, 2025
Read more →

Evogene Subsidiary Lavie Bio's LAV321 Bio-Fungicide Advances To Pre-Commercial Stage After 70% Efficacy Against Downy Mildew In Grapes

EVGN

November 19, 2024
Read more →

Evogene shares are trading higher after the company announced a collaboration with Google Cloud to pioneer a generative AI foundation model for novel small molecule design.

EVGN

October 31, 2024
Read more →

Evogene Announces Collaboration With Google Cloud To Pioneer Generative AI Foundation Model For Novel Small Molecule Design, Leveraging Evogene's Deep Expertise In Computational Predictive Biology And Google Cloud's Leadership In AI And Machine Learning

EVGN

October 31, 2024
Read more →

Aegis Capital Maintains Buy on Evogene, Lowers Price Target to $8

EVGN

September 12, 2022
Read more →